Clinical Trial Update: A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia [Phase 3]

View source ↗

Summary

Phase III trial evaluating safety and efficacy of L-Glutamine for sickle cell disease and sickle β0-thalassemia has completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease
• Sickle Β0-thalassemia

Drugs mentioned

• L-GLUTAMINE (L-Glutamine)

Snippet

Sponsor: Emmaus Medical, Inc. | Conditions: Sickle Cell Anemia, Sickle ß0-Thalassemia | Phase 3 | Status: COMPLETED | Results posted: 2017-08-10